| Followers | 161 |
| Posts | 7130 |
| Boards Moderated | 0 |
| Alias Born | 04/26/2010 |
Saturday, May 22, 2021 1:40:03 PM
McM what are your thoughts (or anybodys) on this post. I am a little behind in this sector.
Bourbon_on_my_cornflakes Friday, 05/21/21 06:49:11 PM
Re: None 0
Post #
311006
of 311051
WHAT IS THE P-VALUE THE FDA REQUIRES??????
"the ANVS401-treated group compared to the placebo group at 25 days showed an improvement of 3.3 points, or 22% (p= 0.13)."
ISN'T P-VAL OF 0.05 OR LESS NORMALLY REQUIRED BY THE FDA??????
MAYBE SOME WALNUTS WOULD HELP?????
Not a threat to AVXL?
Bourbon_on_my_cornflakes Friday, 05/21/21 06:49:11 PM
Re: None 0
Post #
311006
of 311051
WHAT IS THE P-VALUE THE FDA REQUIRES??????
"the ANVS401-treated group compared to the placebo group at 25 days showed an improvement of 3.3 points, or 22% (p= 0.13)."
ISN'T P-VAL OF 0.05 OR LESS NORMALLY REQUIRED BY THE FDA??????
MAYBE SOME WALNUTS WOULD HELP?????
Not a threat to AVXL?
Recent ANVS News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:15:21 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2026 08:12:15 PM
- Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants • GlobeNewswire Inc. • 05/20/2026 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/19/2026 09:25:43 PM
- Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants • GlobeNewswire Inc. • 05/19/2026 08:06:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:30:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:00:58 PM
- Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/15/2026 11:30:00 AM
- Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026 • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 09:02:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:55:10 PM
- Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio • GlobeNewswire Inc. • 04/28/2026 12:00:00 PM
- Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission • GlobeNewswire Inc. • 04/10/2026 12:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/09/2026 09:09:42 PM
- Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants • GlobeNewswire Inc. • 04/09/2026 12:30:00 PM
- The Credibility Filter Wall Street Uses to Sort Biotech Winners • GlobeNewswire Inc. • 04/08/2026 01:15:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2026 08:39:11 PM
- Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections • GlobeNewswire Inc. • 04/02/2026 11:30:00 AM
- Annovis Publishes Historical Review of Buntanetap in The Scientist • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:19:03 PM
- NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 09:06:04 PM
- Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results • GlobeNewswire Inc. • 03/16/2026 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/13/2026 09:15:44 PM
